Search
Danazol
go.drugbank.com/drugs/DB01406ApprovedInvestigationalIt possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. … A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins.
Bezafibrate
go.drugbank.com/drugs/DB01393ApprovedInvestigationalIt decreases low density lipoproteins and increases high density lipoproteins.
Cobamamide
go.drugbank.com/drugs/DB11191ApprovedNutraceuticalin the mitochondria [L2053]. … MeCbl is mainly involved along with folate in hematopoiesis and the growth of the brain during childhood.
Mixtures: EnLyte Extra-LNEquine Botulinum Neurotoxin B Immune FAB2
go.drugbank.com/drugs/DB13903ApprovedIt is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes B in adults and pediatric patients. … Equine Botulinum Neurotoxin B Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype B.
Testolactone
go.drugbank.com/drugs/DB00894ApprovedWithdrawnAn antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer.
Vilobelimab
go.drugbank.com/drugs/DB16416ApprovedInvestigational[L45839] In April 2023, the FDA issued an emergency use authorization (EUA) for vilobelimab for the treatment of COVID-19 in hospitalized adults requiring mechanical ventilation or artificial life support … The drug is not yet fully approved for this condition.[L45849]
Ospemifene
go.drugbank.com/drugs/DB04938ApprovedFDA approved on February 26, 2013. … Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause
Berahyaluronidase alfa
go.drugbank.com/drugs/DB22790ApprovedInvestigationalIt is used in a fixed-dose combination with [pembrolizumab] for subcutaneous injection. … This combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications
Human cord blood hematopoietic progenitor cell
go.drugbank.com/drugs/DB11054ApprovedAfter the first cord blood transplant in 1988 in a patient with Fanconi anemia [A32220], the use of umbilical cord blood transplantation was increased in clinical settings. … Hemacord is marketed in the U.S. as an allogeneic cord blood hematopoietic progenitor cell therapy for intravenous use.
Enasidenib
go.drugbank.com/drugs/DB13874ApprovedInvestigationalgene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345]. … Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2)